AAAAAA
Results: 1-25/26
Authors:
KIM CJ
PARKINSON DR
MARINCOLA F
Citation: Cj. Kim et al., IMMUNODOMINANCE ACROSS HLA POLYMORPHISM - IMPLICATIONS FOR CANCER-IMMUNOTHERAPY, Journal of immunotherapy, 21(1), 1998, pp. 1-16
Authors:
FISHER RI
ROSENBERG SA
SZNOL M
PARKINSON DR
FYFE G
Citation: Ri. Fisher et al., HIGH-DOSE ALDESLEUKIN IN RENAL-CELL CARCINOMA - LONG-TERM SURVIVAL UPDATE, The cancer journal from Scientific American, 3, 1997, pp. 70-72
Authors:
HO PTC
PARKINSON DR
Citation: Ptc. Ho et Dr. Parkinson, ANTISENSE OLIGONUCLEOTIDES AS THERAPEUTICS FOR MALIGNANT DISEASES, Seminars in oncology, 24(2), 1997, pp. 187-202
Authors:
PARKINSON DR
Citation: Dr. Parkinson, NEW PERSPECTIVES AND ADVANCES IN BLOOD MANAGEMENT AND THE TREATMENT OF ANEMIA - INTRODUCTION, Seminars in hematology, 34(3), 1997, pp. 1-3
Authors:
FYFE GA
FISHER RI
ROSENBERG SA
SZNOL M
PARKINSON DR
LOUIE AC
Citation: Ga. Fyfe et al., LONG-TERM RESPONSE DATA FOR 255 PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA TREATED WITH HIGH-DOSE RECOMBINANT INTERLEUKIN-2 THERAPY, Journal of clinical oncology, 14(8), 1996, pp. 2410-2411
Authors:
KELLOFF GJ
CROWELL JA
HAWK ET
STEELE VE
LUBET RA
BOONE CW
COVEY JM
DOODY LA
OMENN GS
GREENWALD P
HONG WK
PARKINSON DR
BAGHERI D
BAXTER GT
BLUNDEN M
DOELTZ MK
EISENHAUER KM
JOHNSON K
KNAPP GG
LONGFELLOW DG
MALONE WF
NAYFIELD SG
SEIFRIED HE
SWALL LM
SIGMAN CC
Citation: Gj. Kelloff et al., STRATEGY AND PLANNING FOR CHEMOPREVENTIVE DRUG DEVELOPMENT - CLINICALDEVELOPMENT PLANS-II, Journal of cellular biochemistry, 1996, pp. 54-71
Authors:
KELLOFF GJ
CROWELL JA
HAWK ET
STEELE VE
LUBET RA
BOONE CW
COVEY JM
DOODY LA
OMENN GS
GREENWALD P
HONG WK
PARKINSON DR
BAGHERI D
BAXTER GT
BLUNDEN M
DOELTZ MK
EISENHAUER KM
JOHNSON K
KNAPP GG
LONGFELLOW DG
MALONE WF
NAYFIELD SG
SEIFRIED HE
SWALL LM
SIGMAN CC
Citation: Gj. Kelloff et al., CLINICAL DEVELOPMENT PLANS FOR CANCER CHEMOPREVENTIVE AGENTS, Journal of cellular biochemistry, 1996, pp. 72-321
Authors:
PLUDA JM
PARKINSON DR
Citation: Jm. Pluda et Dr. Parkinson, CLINICAL IMPLICATIONS OF TUMOR-ASSOCIATED NEOVASCULARIZATION AND CURRENT ANTIANGIOGENIC STRATEGIES FOR THE TREATMENT OF MALIGNANCIES OF PANCREAS, Cancer, 78(3), 1996, pp. 680-687
Authors:
MARINCOLA FM
SHAMAMIAN P
RIVOLTINI L
SALGALLER M
CORMIER J
RESTIFO NP
SIMONIS TB
VENZON D
WHITE DE
PARKINSON DR
Citation: Fm. Marincola et al., HLA ASSOCIATIONS IN THE ANTITUMOR RESPONSE AGAINST MALIGNANT-MELANOMA, Journal of immunotherapy with emphasis on tumor immunology, 18(4), 1995, pp. 242-252
Authors:
PARKINSON DR
Citation: Dr. Parkinson, UNTITLED, Journal of immunotherapy with emphasis on tumor immunology, 17(4), 1995, pp. 4-4
Authors:
FYFE G
FISHER RI
ROSENBERG SA
SZNOL M
PARKINSON DR
LOUIE AC
Citation: G. Fyfe et al., RESULTS OF TREATMENT OF 255 PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA WHO RECEIVED HIGH-DOSE RECOMBINANT INTERLEUKIN-2 THERAPY, Journal of clinical oncology, 13(3), 1995, pp. 688-696
Authors:
PARKINSON DR
SZNOL M
Citation: Dr. Parkinson et M. Sznol, HIGH-DOSE INTERLEUKIN-2 IN THE THERAPY OF METASTATIC RENAL-CELL CARCINOMA, Seminars in oncology, 22(1), 1995, pp. 61-66
Authors:
YANG JC
TOPALIAN SL
SCHWARTZENTRUBER DJ
PARKINSON DR
MARINCOLA FM
WEBER JS
SEIPP CA
WHITE DE
ROSENBERG SA
Citation: Jc. Yang et al., THE USE OF POLYETHYLENE GLYCOL-MODIFIED INTERLEUKIN-2 (PEG-IL-2) IN THE TREATMENT OF PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA AND MELANOMA - A PHASE-I STUDY AND A RANDOMISED PROSPECTIVE STUDY COMPARING IL-2 ALONE VERSUS IL-2 COMBINED WITH PEG-IL-2, Cancer, 76(4), 1995, pp. 687-694
Authors:
PARKINSON DR
Citation: Dr. Parkinson, PRESENT STATUS OF BIOLOGICAL RESPONSE MODIFIERS IN CANCER, The American journal of medicine, 99, 1995, pp. 54-56
Authors:
ROSENBERG SA
YANNELLI JR
YANG JC
TOPALIAN SL
SCHWARTZENTRUBER DJ
WEBER JS
PARKINSON DR
SEIPP CA
EINHORN JN
WHITE DE
Citation: Sa. Rosenberg et al., TREATMENT OF PATIENTS WITH METASTATIC MELANOMA WITH AUTOLOGOUS TUMOR-INFILTRATING LYMPHOCYTES AND INTERLEUKIN-2, Journal of the National Cancer Institute, 86(15), 1994, pp. 1159-1166
Authors:
COLE DJ
SANDA MG
YANG JC
SCHWARTZENTRUBER DJ
WEBER J
ETTINGHAUSEN SE
POCKAJ BA
KIM HI
LEVIN RD
POGREBNIAK HW
BALKISSOON J
FENTON RM
DEBARGE LR
KAYE J
ROSENBERG SA
PARKINSON DR
Citation: Dj. Cole et al., PHASE-I TRIAL OF RECOMBINANT HUMAN MACROPHAGE-COLONY-STIMULATING FACTOR ADMINISTERED BY CONTINUOUS INTRAVENOUS-INFUSION IN PATIENTS WITH METASTATIC CANCER, Journal of the National Cancer Institute, 86(1), 1994, pp. 39-45
Authors:
HAWKINS MJ
ATKINS MB
DUTCHER JP
FISHER RI
WEISS GR
MARGOLIN KA
RAYNER AA
SZNOL M
PARKINSON DR
PAIETTA E
GAYNOR ER
BOLDT DH
DOROSHOW JH
ARONSON FR
Citation: Mj. Hawkins et al., A PHASE-II CLINICAL-TRIAL OF INTERLEUKIN-2 AND LYMPHOKINE-ACTIVATED KILLER-CELLS IN ADVANCED COLORECTAL-CARCINOMA, Journal of immunotherapy with emphasis on tumor immunology, 15(1), 1994, pp. 74-78
Authors:
PARKINSON DR
ARBUCK SG
MOORE T
PLUDA JM
CHRISTIAN MC
Citation: Dr. Parkinson et al., CLINICAL DEVELOPMENT OF ANTICANCER AGENTS FROM NATURAL-PRODUCTS, Stem cells, 12(1), 1994, pp. 30-43
Authors:
GULERIA AS
YANG JC
TOPALIAN SL
WEBER JS
PARKINSON DR
MACFARLANE MP
WHITE RL
STEINBERG SM
WHITE DE
EINHORN JH
SEIPP CA
AUSTIN HA
ROSENBERG SA
SCHWARTZENTRUBER DJ
Citation: As. Guleria et al., RENAL DYSFUNCTION ASSOCIATED WITH THE ADMINISTRATION OF HIGH-DOSE INTERLEUKIN-2 IN 199 CONSECUTIVE PATIENTS WITH METASTATIC MELANOMA OR RENAL-CARCINOMA, Journal of clinical oncology, 12(12), 1994, pp. 2714-2722
Authors:
KELLOFF GJ
CROWELL JA
BOONE CW
STEELE VE
LUBET RA
GREENWALD P
ALBERTS DS
COVEY JM
DOODY LA
KNAPP GG
NAYFIELD S
PARKINSON DR
PRASAD VK
PROROK PC
SAUSVILLE EA
SIGMAN CC
Citation: Gj. Kelloff et al., STRATEGY AND PLANNING FOR CHEMOPREVENTIVE DRUG DEVELOPMENT - CLINICALDEVELOPMENT PLANS, Journal of cellular biochemistry, 1994, pp. 55-303
Authors:
ROSENBERG SA
YANG JC
TOPALIAN SL
SCHWARTZENTRUBER DJ
WEBER JS
PARKINSON DR
SEIPP CA
EINHORN JH
WHITE DE
Citation: Sa. Rosenberg et al., TREATMENT OF 283 CONSECUTIVE PATIENTS WITH METASTATIC MELANOMA OR RENAL-CELL CANCER USING HIGH-DOSE BOLUS INTERLEUKIN-2, JAMA, the journal of the American Medical Association, 271(12), 1994, pp. 907-913
Authors:
PARKINSON DR
Citation: Dr. Parkinson, EXPANDING ROLE OF INTERFERON-ALFA IN THE TREATMENT OF CANCER - INTRODUCTION, Seminars in oncology, 21(6), 1994, pp. 1-1
Authors:
SZNOL M
PARKINSON DR
Citation: M. Sznol et Dr. Parkinson, INTERLEUKIN-2 IN THERAPY OF HEMATOLOGIC MALIGNANCIES, Blood, 83(8), 1994, pp. 2020-2022
Authors:
MARINCOLA FM
BALKISSOON J
SCHWARTZENTRUBER DJ
HOM SS
CONCEPCION R
MARCUS SG
YANNELLI J
TOPALIAN SL
PARKINSON DR
ROSENBERG SA
Citation: Fm. Marincola et al., HEMODYNAMIC-EFFECTS OF THE ADMINISTRATION OF TUMOR-INFILTRATING LYMPHOCYTES TO CANCER-PATIENTS, Journal of immunotherapy with emphasis on tumor immunology, 13(4), 1993, pp. 282-288
Authors:
EDMONSON JH
RYAN LM
BLUM RH
BROOKS JSJ
SHIRAKI M
FRYTAK S
PARKINSON DR
Citation: Jh. Edmonson et al., RANDOMIZED COMPARISON OF DOXORUBICIN ALONE VERSUS IFOSFAMIDE PLUS DOXORUBICIN OR MITOMYCIN, DOXORUBICIN, AND CISPLATIN AGAINST ADVANCED SOFT-TISSUE SARCOMAS, Journal of clinical oncology, 11(7), 1993, pp. 1269-1275